| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Henrik Ryberg | Q56590163 |
| P2093 | author name string | Robert Bowser | |
| P2860 | cites work | Whole-genome analysis of sporadic amyotrophic lateral sclerosis | Q24329076 |
| Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis | Q24678722 | ||
| Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis | Q28131672 | ||
| Astrocyte-endothelial interactions at the blood-brain barrier | Q28131675 | ||
| Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data | Q28943361 | ||
| ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study | Q28943532 | ||
| Amyotrophic lateral sclerosis | Q29619516 | ||
| Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 | ||
| Sample handling for mass spectrometric proteomic investigations of human sera. | Q45966328 | ||
| Low levels of the vascular endothelial growth factor in CSF from early ALS patients. | Q47376496 | ||
| Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? | Q47662929 | ||
| Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS. | Q47776083 | ||
| Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. | Q48183466 | ||
| Large-scale pathways-based association study in amyotrophic lateral sclerosis | Q48199417 | ||
| Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease | Q48241885 | ||
| Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex | Q48357421 | ||
| Decreased cerebrospinal fluid apolipoprotein E after subarachnoid hemorrhage: correlation with injury severity and clinical outcome. | Q48371054 | ||
| Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases | Q48375460 | ||
| VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis | Q48423578 | ||
| Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases | Q48481316 | ||
| Brain-derived neurotrophic factor is not altered in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients. | Q48621555 | ||
| Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations | Q48847858 | ||
| Elevated serum angiogenin levels in ALS. | Q50706850 | ||
| Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. | Q51103719 | ||
| Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. | Q51984385 | ||
| An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. | Q52578937 | ||
| Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. | Q53246758 | ||
| Axonal damage markers in cerebrospinal fluid are increased in ALS. | Q53378093 | ||
| Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls. | Q53816251 | ||
| Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF | Q55952248 | ||
| RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis | Q58125223 | ||
| Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis | Q58478304 | ||
| Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays | Q30661747 | ||
| Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis | Q31143351 | ||
| Identification of potential CSF biomarkers in ALS. | Q33234070 | ||
| The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins | Q33256124 | ||
| Human body fluid proteome analysis | Q33262623 | ||
| Assessment of Protein Stability in Cerebrospinal Fluid Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Protein Profiling | Q33536646 | ||
| Role of oxidative carbonylation in protein quality control and senescence | Q33841697 | ||
| Complex genetics of amyotrophic lateral sclerosis | Q33910597 | ||
| Amyotrophic lateral sclerosis. | Q34004742 | ||
| Genetic epidemiology of amyotrophic lateral sclerosis | Q35083574 | ||
| Global genetic analysis | Q35648274 | ||
| Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. | Q35928006 | ||
| Treatment failure related to intrathecal immunoglobulin M (IgM) synthesis, cerebrospinal fluid IgM, and interleukin-10 in patients with hemolymphatic-stage sleeping sickness | Q35946968 | ||
| Biomarkers and surrogate markers: an FDA perspective | Q36045270 | ||
| Measures and markers in amyotrophic lateral sclerosis | Q36045308 | ||
| Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. | Q36142587 | ||
| Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis | Q36161189 | ||
| The use of biomarkers in the elderly: current and future challenges | Q36194252 | ||
| Biomarkers for amyotrophic lateral sclerosis | Q36481118 | ||
| Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease | Q36615226 | ||
| Alterations in serum thrombospondin in patients with amyotrophic lateral sclerosis | Q36678021 | ||
| Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics | Q36755348 | ||
| Superoxide dismutase and free radicals in sporadic amyotrophic lateral sclerosis: relationship to clinical data | Q36812353 | ||
| Combined biomarkers for early Alzheimer disease diagnosis | Q36822638 | ||
| Genetics of sporadic amyotrophic lateral sclerosis. | Q36958150 | ||
| TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis | Q36965517 | ||
| Protein expression changes in spinal muscular atrophy revealed with a novel antibody array technology. | Q38352797 | ||
| Disease progression and survival in ALS: first multi-state model approach | Q39023321 | ||
| Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases | Q39444706 | ||
| Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis | Q40143586 | ||
| Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress | Q40706061 | ||
| Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis | Q40872318 | ||
| GDNF but not BDNF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis | Q40874154 | ||
| The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis | Q41413618 | ||
| Elevated neurofilament levels in neurological diseases. | Q42450342 | ||
| Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis | Q44029779 | ||
| Multifocal varicella-zoster virus vasculopathy without rash | Q44659582 | ||
| Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum | Q44671632 | ||
| P433 | issue | 2 | |
| P921 | main subject | amyotrophic lateral sclerosis | Q206901 |
| biomarker | Q864574 | ||
| P304 | page(s) | 249-262 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Expert Review of Proteomics | Q15749465 |
| P1476 | title | Protein biomarkers for amyotrophic lateral sclerosis | |
| P478 | volume | 5 |
| Q38847200 | Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. |
| Q33719446 | Applying proteomics to the diagnosis and treatment of ALS and related diseases |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q33392844 | Biomarkers in amyotrophic lateral sclerosis |
| Q37944427 | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations |
| Q33767845 | Blood biomarkers for amyotrophic lateral sclerosis: myth or reality? |
| Q38214427 | Circulating miRNAs as biomarkers for neurodegenerative disorders. |
| Q48713195 | Circulating microRNAs in Neurodegenerative Diseases. |
| Q34792280 | Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. |
| Q28476466 | Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis |
| Q34285662 | Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics |
| Q38856405 | Further development of biomarkers in amyotrophic lateral sclerosis. |
| Q34193281 | Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice |
| Q37487611 | Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis |
| Q58612356 | Machine Learning Reveals Protein Signatures in CSF and Plasma Fluids of Clinical Value for ALS |
| Q34344992 | Mechanisms, models and biomarkers in amyotrophic lateral sclerosis |
| Q60949835 | Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS |
| Q37972903 | Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. |
| Q42369773 | Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement |
| Q37983648 | Spinal cord markers in ALS: diagnostic and biomarker considerations |
| Q33961751 | The application of biomarkers in clinical trials for motor neuron disease |
Search more.